JP2018512394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512394A5 JP2018512394A5 JP2017546847A JP2017546847A JP2018512394A5 JP 2018512394 A5 JP2018512394 A5 JP 2018512394A5 JP 2017546847 A JP2017546847 A JP 2017546847A JP 2017546847 A JP2017546847 A JP 2017546847A JP 2018512394 A5 JP2018512394 A5 JP 2018512394A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- kit
- administered
- pharmaceutical composition
- combination therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 11
- 238000002648 combination therapy Methods 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 10
- 239000003207 proteasome inhibitor Substances 0.000 claims 10
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 9
- 229960001924 melphalan Drugs 0.000 claims 9
- 208000034578 Multiple myelomas Diseases 0.000 claims 7
- 229960001467 bortezomib Drugs 0.000 claims 5
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 5
- 229960002438 carfilzomib Drugs 0.000 claims 5
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 5
- 108010021331 carfilzomib Proteins 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562129221P | 2015-03-06 | 2015-03-06 | |
| US62/129,221 | 2015-03-06 | ||
| US201562153899P | 2015-04-28 | 2015-04-28 | |
| US62/153,899 | 2015-04-28 | ||
| PCT/IB2016/051196 WO2016142814A1 (en) | 2015-03-06 | 2016-03-03 | Roneparstat combined therapy of multiple myeloma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018512394A JP2018512394A (ja) | 2018-05-17 |
| JP2018512394A5 true JP2018512394A5 (enExample) | 2018-12-27 |
Family
ID=55521766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546847A Pending JP2018512394A (ja) | 2015-03-06 | 2016-03-03 | 多発性骨髄腫のロネパルスタット併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10576101B2 (enExample) |
| EP (2) | EP3453389A1 (enExample) |
| JP (1) | JP2018512394A (enExample) |
| KR (1) | KR20170138405A (enExample) |
| CN (1) | CN107645954A (enExample) |
| AU (1) | AU2016230859A1 (enExample) |
| BR (1) | BR112017018869A2 (enExample) |
| CA (1) | CA2978040A1 (enExample) |
| DK (1) | DK3265075T3 (enExample) |
| ES (1) | ES2715556T3 (enExample) |
| HK (1) | HK1245107A1 (enExample) |
| HU (1) | HUE042681T2 (enExample) |
| MX (1) | MX2017011093A (enExample) |
| PL (1) | PL3265075T3 (enExample) |
| PT (1) | PT3265075T (enExample) |
| WO (1) | WO2016142814A1 (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8727157D0 (en) * | 1987-11-19 | 1987-12-23 | Wellcome Found | Pharmaceutical formulations |
| US7781416B2 (en) | 2000-01-25 | 2010-08-24 | Sigma-Tau Research Switzerland S.A. | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| IT1316986B1 (it) | 2000-01-25 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica. |
| EP1427427B1 (en) | 2001-09-12 | 2011-06-08 | SIGMA-TAU Research Switzerland S.A. | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| US20100009934A1 (en) | 2008-06-09 | 2010-01-14 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
-
2016
- 2016-03-03 EP EP18202120.4A patent/EP3453389A1/en not_active Withdrawn
- 2016-03-03 HU HUE16709148A patent/HUE042681T2/hu unknown
- 2016-03-03 PL PL16709148T patent/PL3265075T3/pl unknown
- 2016-03-03 MX MX2017011093A patent/MX2017011093A/es unknown
- 2016-03-03 KR KR1020177026179A patent/KR20170138405A/ko not_active Withdrawn
- 2016-03-03 DK DK16709148.7T patent/DK3265075T3/en active
- 2016-03-03 EP EP16709148.7A patent/EP3265075B1/en active Active
- 2016-03-03 AU AU2016230859A patent/AU2016230859A1/en not_active Abandoned
- 2016-03-03 WO PCT/IB2016/051196 patent/WO2016142814A1/en not_active Ceased
- 2016-03-03 CA CA2978040A patent/CA2978040A1/en not_active Abandoned
- 2016-03-03 CN CN201680012508.0A patent/CN107645954A/zh active Pending
- 2016-03-03 HK HK18104587.1A patent/HK1245107A1/zh unknown
- 2016-03-03 US US15/556,183 patent/US10576101B2/en not_active Expired - Fee Related
- 2016-03-03 JP JP2017546847A patent/JP2018512394A/ja active Pending
- 2016-03-03 PT PT16709148T patent/PT3265075T/pt unknown
- 2016-03-03 BR BR112017018869A patent/BR112017018869A2/pt not_active IP Right Cessation
- 2016-03-03 ES ES16709148T patent/ES2715556T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017226708A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| PH12018550201A1 (en) | Hepatitis b antiviral agents | |
| PH12020550237A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
| EA202090676A1 (ru) | Способы введения некоторых vmat2-ингибиторов | |
| WO2019143902A3 (en) | Substituted heterocycles as antiviral agents | |
| JP2018506550A5 (enExample) | ||
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| PH12020550065A1 (en) | Hepatitis b antiviral agents | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| JP2014532704A5 (enExample) | ||
| HRP20230265T1 (hr) | Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima | |
| JP2018523689A5 (enExample) | ||
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| JP2017525713A5 (enExample) | ||
| JP2020517696A5 (enExample) | ||
| FI4212152T3 (fi) | Sakubitriili-valsartaaniannostusohjelma kroonisen systolisen sydämen vajaatoiminnan hoitoon | |
| JP2018530578A5 (enExample) | ||
| JP2019501226A5 (enExample) | ||
| FI3383385T4 (fi) | Melflufeeniannoskuureja syöpään | |
| TN2022000092A1 (en) | Oral complement factor d inhibitors | |
| MX2018000084A (es) | Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2017524652A5 (enExample) | ||
| JP2016512247A5 (enExample) |